m6A Target Gene Information

General Information of the m6A Target Gene (ID: M6ATAR00340)
Target Name Transcriptional activator Myb (MYB)
Synonyms
Proto-oncogene c-Myb
    Click to Show/Hide
Gene Name MYB
Chromosomal Location 6q23.3
Function
Transcriptional activator; DNA-binding protein that specifically recognize the sequence 5'-YAAC[GT]G-3'. Plays an important role in the control of proliferation and differentiation of hematopoietic progenitor cells.
    Click to Show/Hide
Gene ID 4602
Uniprot ID
MYB_HUMAN
HGNC ID
HGNC:7545
Ensembl Gene ID
ENSG00000118513
KEGG ID
hsa:4602
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
MYB can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Methyltransferase-like 14 (METTL14) [WRITER]
 Regulator Info 
Representative RNA-seq result indicating the expression of this target gene regulated by METTL14
Cell Line MDA-MB-231 Homo sapiens
Treatment: siMETTL14 MDA-MB-231 cells
Control: MDA-MB-231 cells
 GSE81164
Regulation
logFC: 9.21E-01
p-value: 4.44E-04
More Results Click to View More RNA-seq Results
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [1]
Response Summary METTL14 in normal myelopoiesis and AML pathogenesis, as featured by blocking myeloid differentiation and promoting self-renewal of normal HSPCs and LSCs/LICs. METTL14 exerts its oncogenic role by regulating its mRNA targets (e.g., Transcriptional activator Myb (MYB) and MYC) through m6A modification, while the protein itself is negatively regulated by SPI1.
Target Regulation Up regulation
Responsed Disease Acute myeloid leukaemia ICD-11: 2A60
 Disease Info 
Cell Process Cell survival/proliferation
In-vitro Model HEK293T Normal Homo sapiens CVCL_0063
HSPC (Human hematopoietic stem cell)
MNC (Cord blood pluripotent stem cells)
OP9 Normal Mus musculus CVCL_4398
U-937 Adult acute monocytic leukemia Homo sapiens CVCL_0007
In-vivo Model Lin- HSPCs were purified from BM of wildtype mice and 0.1×106 cells were seeded in 2 mL OP9 medium onto the OP9 cells with the addition of 10 ng/mL mouse IL-3, 10 ng/mL human IL-6, 10 ng/mL mouse IL-7, 10 ng/mL mouse Flt-3L, and 50 ng/mL mouse stem cell factor (SCF).
Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) [READER]
 Regulator Info 
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [2]
Response Summary IGF2BP1 decreases leukemia cells' tumorigenicity, promotes myeloid differentiation, increases leukemia cell death, and sensitizes acute myeloid leukemia cells to chemotherapeutic drugs. IGF2BP1 affects proliferation and tumorigenic potential of leukemia cells through critical regulators of self-renewal HOXB4 and Transcriptional activator Myb (MYB) and through regulation of expression of the aldehyde dehydrogenase, ALDH1A1.
Target Regulation Up regulation
Responsed Disease Acute myeloid leukaemia ICD-11: 2A60
 Disease Info 
In-vitro Model MOLT-16 T acute lymphoblastic leukemia Homo sapiens CVCL_1424
Reh B acute lymphoblastic leukemia Homo sapiens CVCL_1650
SKNO-1 Myeloid leukemia with maturation Homo sapiens CVCL_2196
Tanoue B acute lymphoblastic leukemia Homo sapiens CVCL_1852
In-vivo Model For the engraftment experiments, 1×103 1×106 cells were injected into tail veins of non-irradiated 6-10 week-old female mice in 100 uL of DPBS per mouse. No blinding or randomization was applied to mice experiments. Routinely, each in vivo experiment was performed with three technical replicates (three mice per group) and independently repeated two to three times for each cell line.
Acute myeloid leukaemia [ICD-11: 2A60]
 Disease Info 
In total 2 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [2]
Response Summary IGF2BP1 decreases leukemia cells' tumorigenicity, promotes myeloid differentiation, increases leukemia cell death, and sensitizes acute myeloid leukemia cells to chemotherapeutic drugs. IGF2BP1 affects proliferation and tumorigenic potential of leukemia cells through critical regulators of self-renewal HOXB4 and Transcriptional activator Myb (MYB) and through regulation of expression of the aldehyde dehydrogenase, ALDH1A1.
Responsed Disease Acute myeloid leukaemia [ICD-11: 2A60]
Target Regulator Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) READER
 Regulator Info 
Target Regulation Up regulation
In-vitro Model MOLT-16 T acute lymphoblastic leukemia Homo sapiens CVCL_1424
Reh B acute lymphoblastic leukemia Homo sapiens CVCL_1650
SKNO-1 Myeloid leukemia with maturation Homo sapiens CVCL_2196
Tanoue B acute lymphoblastic leukemia Homo sapiens CVCL_1852
In-vivo Model For the engraftment experiments, 1×103 1×106 cells were injected into tail veins of non-irradiated 6-10 week-old female mice in 100 uL of DPBS per mouse. No blinding or randomization was applied to mice experiments. Routinely, each in vivo experiment was performed with three technical replicates (three mice per group) and independently repeated two to three times for each cell line.
Experiment 2 Reporting the m6A-centered Disease Response [1]
Response Summary METTL14 in normal myelopoiesis and AML pathogenesis, as featured by blocking myeloid differentiation and promoting self-renewal of normal HSPCs and LSCs/LICs. METTL14 exerts its oncogenic role by regulating its mRNA targets (e.g., Transcriptional activator Myb (MYB) and MYC) through m6A modification, while the protein itself is negatively regulated by SPI1.
Responsed Disease Acute myeloid leukaemia [ICD-11: 2A60]
Target Regulator Methyltransferase-like 14 (METTL14) WRITER
 Regulator Info 
Target Regulation Up regulation
Cell Process Cell survival/proliferation
In-vitro Model HEK293T Normal Homo sapiens CVCL_0063
HSPC (Human hematopoietic stem cell)
MNC (Cord blood pluripotent stem cells)
OP9 Normal Mus musculus CVCL_4398
U-937 Adult acute monocytic leukemia Homo sapiens CVCL_0007
In-vivo Model Lin- HSPCs were purified from BM of wildtype mice and 0.1×106 cells were seeded in 2 mL OP9 medium onto the OP9 cells with the addition of 10 ng/mL mouse IL-3, 10 ng/mL human IL-6, 10 ng/mL mouse IL-7, 10 ng/mL mouse Flt-3L, and 50 ng/mL mouse stem cell factor (SCF).
References
Ref 1 METTL14 Inhibits Hematopoietic Stem/Progenitor Differentiation and Promotes Leukemogenesis via mRNA m(6)A Modification. Cell Stem Cell. 2018 Feb 1;22(2):191-205.e9. doi: 10.1016/j.stem.2017.11.016. Epub 2017 Dec 28.
Ref 2 RNA-binding protein IGF2BP1 maintains leukemia stem cell properties by regulating HOXB4, MYB, and ALDH1A1. Leukemia. 2020 May;34(5):1354-1363. doi: 10.1038/s41375-019-0656-9. Epub 2019 Nov 25.